May 30, 2013 by Brian Orelli, PhDShould You Trade Pfizer Stock for Shares in Zoetis?An animal of a decision.
May 29, 2013 by Brian Orelli, PhDJohnson & Johnson Stock Takes a BreatherAfter a 12-week run, Johnson & Johnson stock fell last week. Here's what investors should keep an eye on.
May 28, 2013 by Brian Orelli, PhDRight Drug Class, Wrong CompanyAmarin's long-rumored suitor AstraZeneca decides to buy its fish oil competitor Omthera.
May 28, 2013 by Brian Orelli, PhDThe Newest Obesity Drug PlayerNovo Nordisk repurposes its diabetes drug.
May 24, 2013 by Brian Orelli, PhDMerck Stock Is a Good Investment (According to Merck)Merck accelerates its buyback.
May 24, 2013 by Brian Orelli, PhDMerck Stock Is a Good Investment (According to Merck)Merck accelerates its buyback.
May 21, 2013 by Brian Orelli, PhDThe Surprising Link Between ADHD and ObesityThis disorder in childhood could put your adult health at risk.
May 20, 2013 by Brian Orelli, PhDBiotech Companies: The FDA Doesn't Care About Your Phase 3 TrialsResults? Yes. Starting them? Not so much.
May 18, 2013 by Brian Orelli, PhDPick Your Poison: Overweight or High CholesterolResearchers discover that cholesterol-lowering Zocor hindered positive effects of exercise for obese and overweight adults.
May 15, 2013 by Brian Orelli, PhDCancer Meeting Highlights the Good and Bad of the Immune SystemThe immune system can kill tumors, but it can also go haywire.
May 15, 2013 by Brian Orelli, PhDWeight Loss Isn't Just for Looking Good AnymoreMedical benefits are helping obesity drugs get coverage. Will the government help?
May 14, 2013 by Brian Orelli, PhDRacing Toward the Next Hepatitis C Drug ApprovalJohnson & Johnson jumps ahead of Gilead Sciences in the race to bring next-generation hepatitis C drugs to market.
May 13, 2013 by Brian Orelli, PhDDiversifying Royalties at a Hefty CostElan buys 21% of Thervance's royalties on Glaxo's lung drugs.
May 11, 2013 by Brian Orelli, PhDSome Fish Oil Doesn't Help Some Patients in Some CountriesBe careful reading too much into the recently published clinical trial.
May 10, 2013 by Brian Orelli, PhDThe First Step in Treating Type 2 DiabetesMetformin has become doctor's go-to drug.
May 10, 2013 by Brian Orelli, PhDNo Fat in This Drug LaunchAmarin releases sales for the first quarter that Vascepa was on the market.
May 9, 2013 by Brian Orelli, PhDThis Biotech Is Looking for a Fourth-Quarter ComebackAfter a crummy quarter, Dendreon looks to ramp up sales
May 8, 2013 by Brian Orelli, PhDObesity Drug Demand Still LowVIVUS manages just $4.1 million in sales of Qsymia.
May 7, 2013 by Brian Orelli, PhDThe Long Wait for This Obesity Drug Is Almost OverThe DEA issues its final ruling on Belviq, the last step before launch.
